Evidence map›Paper›PMID 30022911›Full record

ArticleCase reports in gastroenterology

Mixed Neuroendocrine Carcinoma and Squamous Cell Carcinoma of the Colon: Case Report and Literature Review.

Shinya Munakata, Yuta Murai, Akihiro Koizumi, Hisaki Kato, Riku Yamamoto, Shuhei Ueda, Satoshi Tokuda, Shunsuke Sakuraba, Tomoyuki Kushida, Hajime Orita and 3 more

Abstract readCase Reports
In one paragraph

Article in Case reports in gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shinya MunakataDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Yuta MuraiDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Akihiro KoizumiDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Hisaki KatoDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Riku YamamotoDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Shuhei UedaDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Satoshi TokudaDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Shunsuke SakurabaDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Tomoyuki KushidaDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Hajime OritaDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Mutsumi SakuradaDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Hiroshi MaekawaDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.
Koichi SatoDepartment of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Izunokuni, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine carcinoma (NEC) of the colon is very rare, and squamous cell carcinoma (SCC) of colon cancer is rare. We recently treated a patient with both NEC and SCC that initially presented as multiple unresectable liver and lung metastases. A 68-year-old Japanese man was referred to our hospital because of diarrhea with descending colon cancer obstruction. He underwent a left colectomy. Based on immunohistochemistry results, we diagnosed mixed NEC and SCC, the primary lesion location of which was probably the lung in the final pathologic examination. He began systemic palliative chemotherapy with CDDP and CPT-11. After 3 months of treatment, shown the progressive disease, we started CDDP and VP-16. The patient was not eligible for additional chemotherapy after 2 months.

Indexed as

Neuroendocrine carcinomaSquamous cell carcinoma

Identifiers

PMID30022911
PMCPMC6047564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.